Chengda Pharmaceuticals Co (SZSE:301201) Long-Term Debt: ¥44.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301201 Chengda Pharmaceuticals Co Ltd SZSE:301201
78 GF Score
Price ¥27.74
GF Value ¥30.45
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengda Pharmaceuticals Co Long-Term Debt?

Chengda Pharmaceuticals Co SZSE:301201 +2.44% 78 Long-Term Debt is ¥44.3 Mil as of Mar. 2026. GuruFocus rates SZSE:301201 with a GF Score™ of 78/100 and a GF Value™ of ¥30.45 (Fairly Valued). The stock has 4 warning signs investors should review.

Chengda Pharmaceuticals Co's Long-Term Debt for the quarter that ended in Mar. 2026 was ¥44.3 Mil.

Chengda Pharmaceuticals Co's quarterly Long-Term Debt declined from Sep. 2025 (¥58.2 Mil) to Dec. 2025 (¥44.3 Mil) but then stayed the same from Dec. 2025 (¥44.3 Mil) to Mar. 2026 (¥44.3 Mil).

Chengda Pharmaceuticals Co's annual Long-Term Debt increased from Dec. 2023 (¥0.0 Mil) to Dec. 2024 (¥80.1 Mil) but then declined from Dec. 2024 (¥80.1 Mil) to Dec. 2025 (¥44.3 Mil).

Chengda Pharmaceuticals Co  (SZSE:301201) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Chengda Pharmaceuticals Co Long-Term Debt Related Terms

Chengda Pharmaceuticals Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Chengda Pharmaceuticals Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengda Pharmaceuticals Co Long-Term Debt Chart

Chengda Pharmaceuticals Co Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 80.12 44.30

Chengda Pharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.20 88.20 58.20 44.30 44.30
SZSE:301201
78GF Score
Chengda Pharmaceuticals Co Ltd SZSE:301201
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥44.3 Mil mean?
Chengda Pharmaceuticals Co (SZSE:301201) has a Long-Term Debt of ¥44.3 Mil as of Mar. 2026.
Is Chengda Pharmaceuticals Co's Long-Term Debt too high?
Chengda Pharmaceuticals Co's current Long-Term Debt is ¥44.3 Mil. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Long-Term Debt compare to ZTS?
Chengda Pharmaceuticals Co's Long-Term Debt of ¥44.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Chengda Pharmaceuticals Co's current Long-Term Debt is ¥44.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥30.45, compared to a current price of ¥27.74 — trading 8.9% below its estimated fair value. The current Long-Term Debt is ¥44.3 Mil. Chengda Pharmaceuticals Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Long-Term Debt is ¥44.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?

Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be undervalued. The current stock price of ¥27.74 is trading 8.9% below its estimated GF Value™ of ¥30.45. GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for SZSE:301201:

  • Long-Term Debt: ¥44.3 Mil
  • GF Value™: ¥30.45 vs. price of ¥27.74 (8.9% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengda Pharmaceuticals Co Business Description

Address 36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
78GF Score

Get the complete analysis for SZSE:301201

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.74
Price
¥30.45
GF Value